ArticleESMO open2026
Efficacy and safety of pembrolizumab-lenvatinib in metastatic endometrial cancer: results from the French multicenter early access program.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPembrolizumab-lenvatinib (P/L) is a standard option for patients with advanced or metastatic endometrial cancer (a/m EC) progressing after platinum-based chemotherapy, based on the KEYNOTE-775 trial. However, concerns remain regarding its real-world applicability, particularly in older, frailer patients and in aggressive histological subtypes underrepresented or excluded from pivotal trials. This study aimed to evaluate the effectiveness and tolerability of P/L in routine practice through the French early access program (EAP). PATIENTS AND
methodsWe conducted a multicenter retrospective analysis of patients treated within the national EAP between March 2022 and December 2023. Eligible patients had histologically confirmed a/m EC progressing after platinum. Pembrolizumab was administered at 200 mg every 3 weeks, and lenvatinib was initiated at up to 20 mg daily. Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier methods, and prognostic factors explored with Cox regression.
resultsA total of 351 patients from 25 centers were included [median age 73 years; 21.5% Eastern Cooperative Oncology Group (ECOG) ≥2]. Carcinosarcomas represented 8.9% of cases. Median PFS was 6.0 months [95% confidence interval (CI) 5.7-8.3], and median OS was 21 months (95% CI 18.6-22.9). Mismatch repair-deficient status was strongly associated with prolonged PFS (16 versus 6 months, P < 0.001). Objective response rate at 6 months was 41%, with a clinical benefit rate of 68%. Independent adverse prognostic factors for PFS included ECOG >1, multiple metastatic sites, microsatellite stable status, and carcinosarcoma subtype. Reduced starting lenvatinib dose (37.2% of patients) did not adversely impact PFS. Permanent discontinuation of lenvatinib because of toxicity was observed in 96 patients (27.6%).
conclusionsP/L demonstrates meaningful activity in a broad real-world population, including older patients with more aggressive disease features and those starting at reduced lenvatinib doses. These findings support the sustained benefit of this combination beyond clinical trial settings, provided that lenvatinib is carefully monitored and doses are personalized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.